{"id":"fluticasone-salmeterol-in-all-asthmatics","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Headache"},{"rate":"1-5%","effect":"Palpitations"},{"rate":"1-5%","effect":"Oral candidiasis"},{"rate":"1-5%","effect":"Nervousness/anxiety"},{"rate":"1-5%","effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is an inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol is a long-acting beta-2 adrenergic agonist (LABA) that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma control.","oneSentence":"Fluticasone/salmeterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing in asthma.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:49.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy in patients ≥4 years of age"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT04503460","phase":"PHASE4","title":"Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2021-07-23","conditions":"Asthma","enrollment":24},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT02061280","phase":"PHASE4","title":"Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2013-10","conditions":"Asthma","enrollment":108},{"nctId":"NCT00708227","phase":"","title":"Pharmacogenetics of b2-Agonists in Asthma.","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2007-09","conditions":"Asthma","enrollment":88},{"nctId":"NCT00315744","phase":"PHASE4","title":"Viapaed Study In Children And Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT00351143","phase":"PHASE4","title":"A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07-26","conditions":"Asthma","enrollment":274},{"nctId":"NCT01347060","phase":"","title":"Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Asthma","enrollment":17448},{"nctId":"NCT01961154","phase":"NA","title":"Stepping Down of Asthma Medication in Controlled Asthma","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Asthma","enrollment":56},{"nctId":"NCT00784485","phase":"PHASE4","title":"Non-invasive Measures of Effects of Xolair in Asthma","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2009-02","conditions":"Asthma","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["symbicort 80/4.5","advair 100/50 or 250/50 or 500/50 bid"],"phase":"marketed","status":"active","brandName":"fluticasone/salmeterol in all asthmatics","genericName":"fluticasone/salmeterol in all asthmatics","companyName":"Gelb, Arthur F., M.D.","companyId":"gelb-arthur-f-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone/salmeterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing in asthma. Used for Asthma maintenance therapy in patients ≥4 years of age, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}